RxDoctor Payments Data

Cheryl Huber, MD

Psychiatry · Bismarck, NDNPI 1114025855

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.2% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.

$1,238in general payments, 2019–2025

Across 62 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$148
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$139
  • Neurocrine Biosciences, Inc.$132
  • Lundbeck LLC$119
  • Teva Pharmaceuticals USA, Inc.$108
  • Alkermes, Inc.$89
  • plus $503 from 11 others

What the payments were for

  • Food & beverage$1,14192%
  • Education$978%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,238 in reported general payments places this provider in the 85th percentile of 63 psychiatry providers in North Dakota.

See all psychiatry providers in North Dakota

Medicare billing

Part B allowed, 2024
$24,688
Medicare patients
162
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lurasidone Hcl58$19,022
Memantine Hcl1,832$14,109
Clozapine163$7,684
Duloxetine Hcl431$5,779
Paliperidone ErPaliperidone46$4,527
Sertraline Hcl851$4,218
Trazodone Hcl647$3,523
Quetiapine Fumarate418$3,474
Mirtazapine544$3,471
Aripiprazole44$3,407
Methylphenidate ErMethylphenidate Hcl21$3,192
Risperidone567$2,900
Olanzapine193$2,725
Ziprasidone Hcl46$2,713
Divalproex Sodium ErDivalproex Sodium109$2,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Loxapine$108$75714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 63 psychiatry providers in North Dakota.

Other psychiatry in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →